TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27398991

Group type: EXPERIMENTAL
Intervention: Walking shoes with triple‐density, variable‐stiffness midsoles and mild lateral‐wedge insoles worn daily
Number of subjects: 164

Group type: COMPARATOR
Intervention: Conventional walking shoes
Number of subjects: 164
Study: 24762371

Group type: COMPARATOR
Intervention: Usual education at the time of hospital discharge
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Special education by nurses during home visits in addition to usual education
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Special education by nurses during home visits
Number of subjects: 110
Study: 23163490

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) scans
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Caliper measurement of centerpoint thickness (CPT)
Number of subjects: 453
Study: 20166156

Group type: EXPERIMENTAL
Intervention: Fractional CO(2) laser treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the comparison between CO(2) and Er:YAG)
Number of subjects: 28
Study: 18296026

Group type: EXPERIMENTAL
Intervention: Coronary Health Improvement Project (CHIP) intervention group
Number of subjects: 348
Study: 15713002

Group type: EXPERIMENTAL
Intervention: Blood orange juice (600 mL/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet without juice
Number of subjects: 16
Study: 12969212

Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/day for 5 days) plus standard care
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 52
Study: 9869719

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 43
Study: 8886750

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone 0.25 U/kg/week (subdivided in daily subcutaneous injections, starting with half the dosage for the first four weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone 0.25 U/kg/week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1352564

Group type: EXPERIMENTAL
Intervention: UW preservation solution
Number of subjects: 695

Group type: COMPARATOR
Intervention: EuroCollins solution
Number of subjects: 695
Study: 6385759

Group type: EXPERIMENTAL
Intervention: Dose 1 of ethyl alcohol resulting in a peak BAC of 100 mg/100 ml
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dose 2 of ethyl alcohol administered when BAC had fallen to one-half the peak BAC from dose 1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo doses administered to five brother-pairs (controls)
Number of subjects: 48
Study: 30206728

Group type: COMPARATOR
Intervention: Post-infusion scalp cooling for 90 minutes
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Post-infusion scalp cooling for 150 minutes
Number of subjects: 102
Study: 29602791

Group type: EXPERIMENTAL
Intervention: Canagliflozin (CANA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Liraglutide (LIRA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Canagliflozin plus Liraglutide (CANA/LIRA)
Number of subjects: 36
Study: 26582520

Group type: EXPERIMENTAL
Intervention: Web-based intervention (BeInCharge.org [BIC])
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Care Control (STC)
Number of subjects: 10
Study: 25128520

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly plus Methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 0
Study: 22325110

Group type: EXPERIMENTAL
Intervention: 0.4 mg norethindrone (NET)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 1.0 mg norethindrone (NET)
Number of subjects: 33
Study: 19559380

Group type: EXPERIMENTAL
Intervention: Screening group (n=42,590)
Number of subjects: 84781

Group type: COMPARATOR
Intervention: Control group (n=42,191)
Number of subjects: 84781
Study: 17148582

Group type: EXPERIMENTAL
Intervention: Horse ATG/Cyclosporine (HC)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Horse ATG/Cyclosporine/Sirolimus (HCS)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rabbit ATG/Cyclosporine (RC)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (CP)
Number of subjects: 78
Study: 16167234

Group type: EXPERIMENTAL
Intervention: BCAA enriched formula
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine amino acid
Number of subjects: 40
Study: 11980678

Group type: EXPERIMENTAL
Intervention: phVEGF2 (200 microg, 800 microg, or 2000 microg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: phVEGF2
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9460820

Group type: EXPERIMENTAL
Intervention: Intervention program for Type A behavior
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 8590535

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 77

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Patients with ST shift > or = 60 min
Number of subjects: 77
Study: 2171852

Group type: COMPARATOR
Intervention: Oral amiloride 20 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Inhaled amiloride 10 ml of 10(‐2) mol/l
Number of subjects: 43
Study: 9581

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (C) 10 mg t.i.d. for 7 days, 20 mg t.i.d. for 7 days + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Thioridazine (T) 10 mg t.i.d. for 7 days, 20 mg t.i.d. for 7 days
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sulpiride (S) 50 mg t.i.d. + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bromazepam (B) 6 mg t.i.d. + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Thioridazine (T) + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (C) + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sulpiride (S) + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bromazepam (B) + Alcohol (A) 0.5 g/kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 37
Study: 30508769

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 40
Study: 28703504

Group type: EXPERIMENTAL
Intervention: MEND/CATCH6-12 (121.5 contact hours)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Next Steps (8 contact hours)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: MEND2-5 (27 contact hours)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Both programs
Number of subjects: 549

Group type: COMPARATOR
Intervention: MEND/CATCH6-12 and Next Steps
Number of subjects: 549
Study: 26316279

Group type: EXPERIMENTAL
Intervention: Learning conversation
Number of subjects: 640

Group type: COMPARATOR
Intervention: Sandwich technique
Number of subjects: 640
Study: 23944208

Group type: EXPERIMENTAL
Intervention: Sedation assessment using a scale in intubated and ventilated patients
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Pain assessment
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Moderate pain
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Sedation levels assessment
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Delirium assessment
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Use of restraints
Number of subjects: 569
Study: 20675107

Group type: EXPERIMENTAL
Intervention: Red meat consumption (quintiles of intake)
Number of subjects: 21120
Study: 18520336

Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, Bifidobacterium lactis, Streptococcus thermophilus, Lactobacillus reuteri)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, Bifidobacterium spp., Streptococcus spp., Saccharomyces boulardii)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, S. boulardii, L. reuteri)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus GG, S. boulardii)
Number of subjects: 0
Study: 13678108

Group type: EXPERIMENTAL
Intervention: DentiPatch (lidocaine patch)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Benzocaine gel
Number of subjects: 30
Study: 10618302

Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT) frequency
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Clinical variables
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmias
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Asymptomatic NSVT on ambulatory ECG
Number of subjects: 1080
Study: 8885036

Group type: EXPERIMENTAL
Intervention: Whiplash injury patients
Number of subjects: 30
Study: 1597844

Group type: EXPERIMENTAL
Intervention: 4g of an oil preparation rich in C18:3n-6, C20:5n-3 and C22:6n-3
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4g sunflower seed oil
Number of subjects: 18
Study: 6204153

Group type: EXPERIMENTAL
Intervention: Diuretics as sole therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics combined with alpha-methyldopa or propranolol
Number of subjects: 0
Study: 30264178

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 6
Study: 29072209

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 24
Study: 26216382

Group type: EXPERIMENTAL
Intervention: Febuxostat (fixed dose 120 mg)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Allopurinol (low/standard/high doses: 200/300/600 mg)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Both febuxostat and allopurinol
Number of subjects: 346
Study: 24352085

Group type: EXPERIMENTAL
Intervention: 500 mg allopurinol intravenously to the mother immediately prior to delivery
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 22929602

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acupuncture with percutaneous electrical nerve stimulation (PENS)
Number of subjects: 20
Study: 20712602

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Thermal balloon endometrial ablation (TBALL)
Number of subjects: 314
Study: 17554155

Group type: EXPERIMENTAL
Intervention: Feedback plus information (FB+I)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Feedback (FB)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 177
Study: 15661234

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m², Carboplatin AUC 5, Gemcitabine 800 mg/m² on day 1 and Gemcitabine 800 mg/m² on day 8, every 3 weeks
Number of subjects: 55
Study: 12028981

Group type: EXPERIMENTAL
Intervention: Intervention group (general practitioner letter inviting consultation and management guidelines)
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Control group (usual general practitioner care)
Number of subjects: 1932

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1932
Study: 10468948

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 15 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 20 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quality of life assessments (BBS, Bf-S, BL)
Number of subjects: 9
Study: 7533447

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TUMT
Number of subjects: 0
Study: 1694831

Group type: EXPERIMENTAL
Intervention: Iloprost infusion (2-4 ng/kg/min for 12 hours daily on 5 consecutive days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dextran infusion
Number of subjects: 13
Study: 293032

Group type: EXPERIMENTAL
Intervention: Adaptic (standard composite material)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estic microfill (newly developed composite material)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amalgam (Dispersalloy)
Number of subjects: 0
Study: 31774950

Group type: EXPERIMENTAL
Intervention: MAb114
Number of subjects: 681

Group type: COMPARATOR
Intervention: ZMap
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: REGN-EB3
Number of subjects: 681

Group type: COMPARATOR
Intervention: ZMap subgroup
Number of subjects: 681
Study: 27876559

Group type: EXPERIMENTAL
Intervention: Non-dominant hand for puncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dominant hand for puncture
Number of subjects: 20
Study: 25867847

Group type: EXPERIMENTAL
Intervention: Antioxidant supplements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 23046314

Group type: EXPERIMENTAL
Intervention: School-based humanistic counseling (SBHC) for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 33
Study: 21098802

Group type: EXPERIMENTAL
Intervention: 6-monthly screening
Number of subjects: 22634

Group type: COMPARATOR
Intervention: 12-monthly screening
Number of subjects: 22634
Study: 19251004

Group type: EXPERIMENTAL
Intervention: Transparent hood
Number of subjects: 592

Group type: COMPARATOR
Intervention: No hood
Number of subjects: 592
Study: 18317624

Group type: EXPERIMENTAL
Intervention: Midazolam 40 microg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Diazepam 40 microg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 microg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of midazolam and clonidine (40 microg/kg and 0.5 microg/kg respectively)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combination of diazepam and clonidine (40 microg/kg and 0.5 microg/kg respectively)
Number of subjects: 160
Study: 15774240

Group type: EXPERIMENTAL
Intervention: Chemotherapy with vinorelbine and estramustine phosphate plus ellagic acid (group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy with vinorelbine and estramustine phosphate (group A)
Number of subjects: 0
Study: 12399790

Group type: EXPERIMENTAL
Intervention: Computer-based health promotion screening
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 248
Study: 9865561

Group type: EXPERIMENTAL
Intervention: Cefuroxime (prophylactic dose)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Trimethoprim and sulfamethoxazole
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 99
Study: 8556030

Group type: EXPERIMENTAL
Intervention: Co-culture of embryos with Vero cell monolayer
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional culture without Vero cell monolayer
Number of subjects: 75
Study: 2294131

Group type: EXPERIMENTAL
Intervention: Evening GH injections (2000 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Morning GH injections (0800 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No GH administration
Number of subjects: 8
Study: 368086

Group type: EXPERIMENTAL
Intervention: Pirprofen (600 mg per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Aspirin (3600 mg per day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 35

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 35
Study: 31913829

Group type: EXPERIMENTAL
Intervention: Cadaver training
Number of subjects: 78

Group type: COMPARATOR
Intervention: Manikin training
Number of subjects: 78
Study: 30052592

Group type: EXPERIMENTAL
Intervention: Medication-Assisted Treatment (MAT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Significant relationships with healthcare providers
Number of subjects: 10
Study: 27966508

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autogenous bone graft (ABG)
Number of subjects: 20
Study: 23180287

Group type: EXPERIMENTAL
Intervention: PMT + action-planning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PMT + action-and-coping-planning
Number of subjects: 60

Group type: COMPARATOR
Intervention: PMT-only
Number of subjects: 60
Study: 22133627

Group type: EXPERIMENTAL
Intervention: Inhibition training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Imitation training
Number of subjects: 24

Group type: COMPARATOR
Intervention: General inhibition training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study: 20457817

Group type: COMPARATOR
Intervention: CXA-101 (single doses of 250, 500, 1,000, 1,500, and 2,000 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: CXA-101 (multiple doses of 500 mg every 8 h, 1,000 mg every 8 h, and 1,500 mg every 12 h for 10 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CXA-101 (1-hour infusion)
Number of subjects: 64
Study: 17920365

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 509

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 509
Study: 15932167

Group type: EXPERIMENTAL
Intervention: Anti-reflux surgery (open or laparoscopic fundoplication)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Medical care (non-operated controls)
Number of subjects: 373
Study: 12456849

Group type: EXPERIMENTAL
Intervention: Miltefosine (50 or 100 mg daily for 28 days)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Amphotericin B (1 mg per kilogram every other day for a total of 15 injections)
Number of subjects: 398
Study: 10350032

Group type: EXPERIMENTAL
Intervention: Pemoline (3 mg/kg per day, mean dose 2.2 mg/kg per day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 7668935

Group type: EXPERIMENTAL
Intervention: Electrofocusing technique for serum alkaline phosphatase isoenzymes
Number of subjects: 135
Study: 2401750

Group type: EXPERIMENTAL
Intervention: Maxzide (25 mg of hydrochlorothiazide and 37.5 mg of triamterene)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dyazide (25 mg of hydrochlorothiazide and 50 mg of triamterene)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maxzide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dyazide
Number of subjects: 30
Study: 453712

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscopy followed by respiratory therapy for 48 hours
Number of subjects: 31

Group type: COMPARATOR
Intervention: Respiratory therapy alone for 48 hours
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 31922429

Group type: EXPERIMENTAL
Intervention: Ads with the phrase 'tobacco and water'
Number of subjects: 1577

Group type: EXPERIMENTAL
Intervention: Ads with all tactics together
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Eco-friendly language and plant imagery
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Control condition (none of the tactics)
Number of subjects: 1577
Study: 31789006

Group type: EXPERIMENTAL
Intervention: Pressure-controlled hemostasis (systolic blood pressure + 20 mmHg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional hemostasis (15 mL air injection)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 86
Study: 30910149

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA), 1 capsule/day starting from the 21st day of the cycle prior to gonadotropin stimulation.
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo, 1 capsule/day starting from the 21st day of the cycle prior to gonadotropin stimulation.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 28609257

Group type: EXPERIMENTAL
Intervention: Palliative care (PC) intervention
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 178
Study: 26724241

Group type: EXPERIMENTAL
Intervention: Blended Infant Massage-Parenting Enhancement Program (IMPEP)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Parenting Enhancement Program (PEP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (standard care parenting resources)
Number of subjects: 138
Study: 23702621

Group type: EXPERIMENTAL
Intervention: Cefazolin or clindamycin before skin incision
Number of subjects: 896

Group type: COMPARATOR
Intervention: Cefazolin or clindamycin after cord clamp
Number of subjects: 896
Study: 21334262

Group type: EXPERIMENTAL
Intervention: Glycerol (75 mL four times a day for 4 days)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo (sugar solution equivalent volume)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 19374148

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) examination of the tongue base
Number of subjects: 41

Group type: COMPARATOR
Intervention: Polysomnography
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physical examination
Number of subjects: 41
Study: 16886163

Group type: EXPERIMENTAL
Intervention: Single-dose lopinavir-ritonavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 15237694

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched intravenous placebo
Number of subjects: 30
Study: 11157690

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 19768
Study: 9024728

Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent implantation
Number of subjects: 533

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 533